ライフサイエンスコーパス: metastatic disease

1 ent, and 18 with neuroblastoma without brain metastatic disease).

2 etion of first-line/initial chemotherapy for metastatic disease.

3 o localized prostate cancer and subsequently metastatic disease.

4 h solid malignancy, only 51 (17 %) had known metastatic disease.

5 with the liver being the most common site of metastatic disease.

6 efits of this drug in patients with advanced metastatic disease.

7 umor phenotype in vivo and mirror late stage metastatic disease.

8 alized treatment strategies in patients with metastatic disease.

9 apeutic target to prevent the development of metastatic disease.

10 esent with localised or locally advanced non-metastatic disease.

11 of alterations associated with recurrent and metastatic disease.

12 strategies aimed at preventing and treating metastatic disease.

13 , and greatly extended survival of mice with metastatic disease.

14 Staging scans were negative for metastatic disease.

15 t may change clinical approaches to managing metastatic disease.

16 of alterations associated with recurrent and metastatic disease.

17 lished tumors and a significant reduction in metastatic disease.

18 ervention in the prevention and treatment of metastatic disease.

19 nd more than 50% of patients presenting with metastatic disease.

20 tastatic disease and 3 patients with osseous metastatic disease.

21 t, abdomen, and pelvis showed no evidence of metastatic disease.

22 e more successful treatment of heterogeneous metastatic disease.

23 r of carcinoma invasiveness and a target for metastatic disease.

24 in the battle against cancer, especially the metastatic disease.

25 There was no evidence of metastatic disease.

26 in prostate cancer (PCa) and associated with metastatic disease.

27 There was no evidence of local or distant metastatic disease.

28 apy and improve progression-free survival in metastatic disease.

29 ating intrahepatic HCC even in patients with metastatic disease.

30 cancer and 1 had high clinical suspicion of metastatic disease.

31 l ranges from 74% to 91% in patients without metastatic disease.

32 reduces primary tumor volume and eliminates metastatic disease.

33 uvant endocrine therapy and in HT refractory metastatic disease.

34 ations for therapeutic targeting of advanced metastatic disease.

35 overcome recurrence of vemurafenib-resistant metastatic disease.

36 nge in the incidence of invasive and distant metastatic disease.

37 androgen synthesis and act as analgesics for metastatic disease.

38 challenging, particularly in the setting of metastatic disease.

39 n primary colorectal tumors of patients with metastatic disease.

40 onal signatures for phylogenetic tracking of metastatic disease.

41 n cancer types with no effective therapy for metastatic disease.

42 ing primary tumour growth and progression to metastatic disease.

43 he entire tumor, and across distant sites of metastatic disease.

44 instability) contribute to the evolution of metastatic disease.

45 s information is important in the setting of metastatic disease.

46 vival rate of only 12% for patients with the metastatic disease.

47 cer-related deaths, primarily due to distant metastatic disease.

48 nd novel treatment regimens in patients with metastatic disease.

49 21 patients with either locally advanced or metastatic disease.

50 eria in Solid Tumors (RECIST) for measurable metastatic disease.

51 st patients present with locally advanced or metastatic disease.

52 ty, local recurrence, and the development of metastatic disease.

53 during organogenesis, immune responses, and metastatic disease.

54 l review, as did four (17%, 5-39) of 23 with metastatic disease.

55 nd-, or third-line chemotherapy for advanced/metastatic disease.

56 d from analysis, as were VOIs not related to metastatic disease.

57 so be effective in controlling the growth of metastatic disease.

58 tment for patients with locally advanced and metastatic disease.

59 hway as a predictive biomarker for recurrent metastatic disease.

60 ent (survivorship), and after diagnosis with metastatic disease.

61 od; their detection is used predominantly in metastatic disease.

62 ed the recovery of symptomatic patients with metastatic disease.

63 s, respectively, received drug treatment for metastatic disease.

64 ferate and differentiate to produce advanced metastatic disease.

65 tial for the development of solid tumors and metastatic disease.

66 mutations has become a standard of care for metastatic disease.

67 extraprostatic findings on PET suggestive of metastatic disease.

68 cal outcome between hepatic and extrahepatic metastatic disease.

69 cinoma and two (15%, 2-45) among the 13 with metastatic disease.

70 for control of the primary site and possible metastatic disease.

71 ctal cancer, and is strongly associated with metastatic disease.

72 ride PET/CT scans for evaluation of skeletal metastatic disease.

73 both typically are caused by development of metastatic disease.

74 se pathways represent therapeutic targets in metastatic disease.

75 R-targeted antibody therapy for recurrent or metastatic disease.

76 erapy; 51% had received >/= two regimens for metastatic disease.

77 rostate cancer patients prone to progress to metastatic disease.

78 with poor risk and those with recurrent and metastatic disease.

79 roblem, because it often involves inoperable metastatic disease.

80 otype is a key hallmark of iodide-refractory metastatic disease.

81 recapitulate many important facets of human metastatic disease.

82 ith Sativex warrants clinical evaluation for metastatic disease.

83 therapeutic strategies to treat and prevent metastatic disease.

84 y for the management of locally advanced and metastatic disease.

85 0 years and eventually progress to incurable metastatic disease.

86 y correlated positively with the presence of metastatic disease.

87 ere compared with patients with disseminated metastatic disease.

88 or prevents progression of both primary and metastatic disease.

89 ived chemotherapy for unresectable recurrent/metastatic disease.

90 ns, especially in the context of surgery and metastatic disease.

91 remain at risk for local recurrences and/or metastatic disease.

92 optotic elimination of advanced invasive and metastatic disease.

93 ally significant PCa and with progression to metastatic disease.

94 nd GSS in AYA patients, including those with metastatic disease.

95 eatment approach exists for the treatment of metastatic disease.

96 rathoracic lymph nodes only) or disseminated metastatic disease.

97 nonmetastatic disease and 0.31 in those with metastatic disease.

98 th lung cancer, particularly in advanced and metastatic disease.

99 biomarker of disease progression and perhaps metastatic disease.

100 avenous contrast demonstrated no evidence of metastatic disease.

101 cted survival of neuroblastoma patients with metastatic disease.

102 ard treatment for patients with advanced and metastatic disease.

103 atient developed externalization of tumor or metastatic disease.

104 dearth of effective therapeutic options for metastatic disease.

105 ortality and morbidity reported for advanced metastatic disease.

106 ent demonstrated externalization of tumor or metastatic disease.

107 rine resistance especially in the setting of metastatic disease.

108 esent a therapeutic opportunity for managing metastatic disease.

109 Staging scans were negative for metastatic disease.

110 nonmetastatic disease and 0.61 in those with metastatic disease.

111 d into developing ceramide-based therapy for metastatic diseases.

112 and lead to novel therapeutic strategies for metastatic diseases.

113 imens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involveme

114 18 vs 11 years; P = .04) and the presence of metastatic disease (1 patient vs none; P = .05) were ass

115 A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indete

116 milar to those of unenhanced PET/CT (distant metastatic disease: 28 of 29 [96%] for readers 3 and 4,

117 In the OAC group, there were 3 cases of metastatic disease (4.2%) and no deaths.

118 agnosed with pancreatic cancer (41 [34%] had metastatic disease), 47 (12%) with other cancers, and 22

119 % CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively).

120 The enucleation group had 5 cases of metastatic disease (7.9%) and 2 deaths (3.2%).

121 eived two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% wer

122 as significantly increased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95

123 Dormant breast cancers resurge as metastatic disease after a long dormancy period in the b

124 lopment, local tumor recurrence, presence of metastatic disease after surgery, and sufficiency of the

125 Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and impr

126 included in this analysis, of whom 20 had no metastatic disease and 20 had metastasis.

127 48 samples across 3 patients with lymph node metastatic disease and 3 patients with osseous metastati

128 ble clinical responses in some patients with metastatic disease and a reasonable response rate in man

129 An additional 13 patients (1.3%) developed metastatic disease and are alive with confirmed metastas

130 neity in subclonal structure from primary to metastatic disease and between metastatic sites, such th

131 eatments for cancer, they can rarely control metastatic disease and cures remain scarce.

132 ical stage T1c-3, cN0, cN1, or cN2a, without metastatic disease and diagnosed by core needle biopsy.

133 gh curative treatment into survivorship, and metastatic disease and end-of-life care.

134 hildren, frequently presents with aggressive metastatic disease and for these children the 5-year sur

135 herapy who had received no prior therapy for metastatic disease and had Karnofsky performance score >

136 limiting local progression and outgrowth of metastatic disease and maintaining quality of life.

137 tumors and its expression is associated with metastatic disease and poorer survival.

138 ctional imaging confirmed widespread osseous metastatic disease and right supraclavicular lymph node

139 t, associated with poor median survivals for metastatic disease and significant, sometimes prolonged,

140 e useful for the evaluation of the extent of metastatic disease and the assessment of the therapy res

141 ET/CT enables discrimination of local versus metastatic disease and thus might have a crucial impact

142 in the tumor, and no prior chemotherapy for metastatic disease and were treated with erlotinib or ch

143 our cohort, 2.8% of patients have developed metastatic disease, and 1.5% have died of prostate cance

144 up performance status of 0 or 1, progressive metastatic disease, and adequate haematological, renal,

145 onary resuscitation, previous ICU admission, metastatic disease, and admission for respiratory reason

146 tors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL o

147 een implicated as a driver of aggressive and metastatic disease, and is upregulated during glioblasto

148 east cancer development and the promotion of metastatic disease, and its expression in breast tumors

149 ould prove useful in determining the risk of metastatic disease, and its manipulation might offer a n

150 ssociated with aggressive cancer phenotypes, metastatic disease, and poor patient prognosis, and depl

151 phy scan of the pelvis showed no evidence of metastatic disease, and the patient underwent a robotic-

152 stem cell properties are key contributors to metastatic disease, and there remains a need to better u

153 larly in the context of tumor heterogeneity, metastatic disease, and treatment response.

154 Patients who present with metastatic disease are consigned to stage 4, and the TNM

155 therapeutic options for locally advanced or metastatic disease are limited.

156 ng increasingly common because patients with metastatic disease are living longer.

157 Kaplan-Meier estimate for absence of metastatic disease at 5 years was 78.5% (95% CI, 54.77%-

158 ely to have Gleason scores >/= 8 ( P = .05), metastatic disease at diagnosis ( P = .01), higher PSA (

159 ification on the basis of the burden of lung metastatic disease at diagnosis.

160 reader 1, seven of eight [88%] for reader 2) metastatic disease at rates similar to those of unenhanc

161 ab with no evidence of disease recurrence or metastatic disease at study entry.

162 rimary therapy has the potential to identify metastatic disease at the earliest stage, enabling initi

163 Ovarian cancer (OC) is a highly metastatic disease, but no effective strategies to targe

164 adenocarcinoma (PDAC) invariably succumb to metastatic disease, but the underlying mechanisms that r

165 therapeutic approaches to prevent or target metastatic disease by harnessing NK cells.

166 cascade and the establishment of aggressive, metastatic disease by reactivating a latent embryonic pr

167 wever, disease recurrence and development of metastatic disease can occur despite appropriate treatme

168 We generated xenograft models of HTR metastatic disease characterized by EVs in the periphera

169 For metastatic disease, chemotherapy as initial treatment no

170 ccessful sentinel-lymph-node mapping who had metastatic disease correctly identified in the sentinel

171 Early detection of recurrent or metastatic disease could improve patient prognosis by tr

172 patients, and especially those with advanced metastatic disease, deep sequencing of circulating cell

173 ers (TNBC) are at high risk for recurrent or metastatic disease despite standard treatment, underscor

174 udied the role of fetuin glycoprotein on the metastatic disease diagnosis.

175 mutations in DNA-repair genes among men with metastatic disease did not differ significantly accordin

176 e relapse after early stage disease, de novo metastatic disease, discordant disease response, and dis

177 eractions and discover rare cells that drive metastatic disease, drug resistance and disease progress

178 [IQR], 38-93), 175 patients (94%) developed metastatic disease; each had abdominal disease, and 76 (

179 ic benefit, in both early and advanced stage metastatic disease, especially when used as a maintenanc

180 tantly, microvesicles from patients with HTR metastatic disease expressed high levels of miR-221.

181 The remaining 21 cases showed no signs of metastatic disease for an average follow-up of 10 years.

182 ard of complete lymphadenectomy in detecting metastatic disease for endometrial cancer.

183 squamous cell carcinoma of the anus without metastatic disease from 59 centres in the UK.

184 be exploited in a clinical setting to target metastatic disease from multiple angles.

185 Prior to therapy, some patients with metastatic disease had elevated antibodies to IGFBP2, p5

186 Patients with metastatic disease had significantly higher serum levels

187 ital mortality rate in ICU patients (42.8%); metastatic disease had the highest mortality rate in non

188 etween chemotherapy and QOL amid progressive metastatic disease has not been well-studied.

189 Acute liver failure (ALF) induced by diffuse metastatic disease has rarely been reported.

190 er understanding of the genetic evolution of metastatic disease has the potential to reveal differenc

191 2-3.17, p=0.0056), especially for those with metastatic disease (HR 2.22, 1.00-4.93, p=0.050).

192 ence (HR, 1.97; 95% CI, 0.11-3.48; P = .02), metastatic disease (HR, 2.51; 95% CI, 1.07-5.91; P = .03

193 counsel patients regarding ongoing risks of metastatic disease, implications for surveillance, and s

194 locoregional lymph nodes in 39%, and distant metastatic disease in 16%.

195 at DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24%; increased and de

196 uclear BAP1 had decreased odds of developing metastatic disease in a multivariate model (P = 0.042).

197 e to achieve complete durable regressions of metastatic disease in a murine model of metastatic breas

198 The emergence of metastatic disease in cancer patients many years or deca

199 ow that PCS1 tumors progress more rapidly to metastatic disease in comparison with PCS2 or PCS3, incl

200 In patients without baseline metastasis, metastatic disease in follow-up was considerably higher

201 orafenib) to successfully treat postsurgical metastatic disease in multiple orthotopically implanted

202 of MDM2-ALT1 has been observed in aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS),

203 ence for clinical trials in the treatment of metastatic disease in the second-line setting.

204 he only significant independent predictor of metastatic disease in this study.

205 the size of the primary tumor and prevented metastatic disease in vivo The antitumor effect correlat

206 ed tumours with excellent outcomes to widely metastatic disease in which long-term survival is approx

207 In patients without metastatic disease, incidental focal [18]FDG uptake in t

208 In metastatic disease, increased percentage of tumors with

209 nnovative preclinical model systems to study metastatic disease; increased sharing of resources and d

210 Progression to metastatic disease is a leading cause of cancer death.

211 Progressive metastatic disease is a major cause of mortality for pat

212 The most standard chemotherapy for metastatic disease is gemcitabine plus cisplatin based o

213 The incidence of brain metastatic disease is increasing with the improved manag

214 Current understanding of metastatic disease is limited due to difficulty of sampl

215 Metastatic disease is the leading cause of cancer-relate

216 Metastatic disease is the major cause of breast cancer-r

217 ocal treatment (LT), even in the presence of metastatic disease, is beneficial.

218 ccurring metastases-that is, treatment-naive metastatic disease-is largely unknown.

219 During treatment of metastatic disease, it is useful to predict response and

220 fluoride (NaF PET) for assessment of osseous metastatic disease led to changes in intended management

221 nfirmation of stage IV NSCLC, three or fewer metastatic disease lesions after first-line systemic the

222 00 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all

223 Metastatic disease (M1) is classified as ICON-S stage IV

224 nths), 401 of 631 (63.5%) patients developed metastatic disease (median interval, 6.9 months; interqu

225 246-12,856 ng/mL]) than did patients without metastatic disease (median level, 296 ng/mL [range, 201-

226 esence of cCAFs in 30/34 (88%) patients with metastatic disease (MET group) and in 3/13 (23%) patient

227 ent risk factors for hospital mortality were metastatic disease (odds ratio, 1.99), cardiopulmonary r

228 iagnosed colon cancer were not known to have metastatic disease of their primary tumor.

229 Pelvic nodal and extrapelvic metastatic disease on (68)Ga-PSMA-11 PET/CT (PSMA T0N1M0

230 isease secondary to sarcoidosis, mimicking a metastatic disease on ultrasonography and CT.

231 On subset analysis of 91 AYA patients with metastatic disease, operative management was associated

232 atic carcinoma or who subsequently developed metastatic disease or local pelvic recurrence after radi

233 gical complications directly attributable to metastatic disease or other concurrent cancer-related tr

234 romatase inhibitor treatment for advanced or metastatic disease or relapse during or within 6 months

235 postdiagnosis imaging to assess for distant metastatic disease (OR, 1.51; 95% CI, 1.42-1.61), mastec

236 o increase the chance of orbital recurrence, metastatic disease, or death compared with primary enucl

237 patients with poor-prognosis primary tumors, metastatic disease, or hematologic malignant neoplasms a

238 ere better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic t

239 In 8 patients with metastatic disease outside the abdomen, 4 patients had l

240 cer with >/= three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcita

241 About 50% of patients will develop metastatic disease primarily to the liver and the lung.

242 lly initiate neuroblastoma and contribute to metastatic disease progression.

243 found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time.

244 nts with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doub

245 n whose expression correlates with increased metastatic disease, reduced patient survival and poor pr

246 increasing, survival rates for patients with metastatic disease remain <10%.

247 kers and efficacious targeted treatments for metastatic disease remain lacking.

248 ible factor activity, but their functions in metastatic disease remain unclear.

249 of cancer death in American men, and curing metastatic disease remains a significant challenge.

250 Although the standard of care for metastatic disease remains cytotoxic therapy, a variety

251 is the most common primary bone tumor, with metastatic disease responsible for most treatment failur

252 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for readers 3 a

253 Metastatic disease should be considered when a salivary

254 Preplanned subgroup analyses in men with metastatic disease showed a hazard ratio of 0.78 (95% CI

255 Patients with progressive metastatic disease showed further increases in sc-Met le

256 isk factors (p=0.0403) and higher numbers of metastatic disease sites (p=0.0414) were associated with

257 hich matched normal tissue, primary PDAC and metastatic disease sites were available, insertions were

258 ted radiometals to deliver beta-radiation to metastatic disease sites, with (177)Lu being the most wi

259 HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than

260 val, yet tumor resistance and progression of metastatic disease still develop over time.

261 To reduce the risk of subsequent metastatic disease, systemic chemotherapy can be introdu

262 like breast carcinoma present with invasive, metastatic disease that do not respond to available ther

263 TCs) have a great potential as indicators of metastatic disease that may help physicians improve canc

264 cells had potent synergistic effects against metastatic disease that was already established in secon

265 xifen as first-line therapy for recurrent or metastatic disease, the expression levels of the recepto

266 ients with short survival times (</=3 mo) or metastatic disease, the total cost per patient did not d

267 Consequently, in metastatic disease, the utility of external-beam radioth

268 initiation is well established, its role in metastatic diseases, the primary cause of cancer deaths,

269 idence of cancer is increasing worldwide and metastatic disease, through the spread of circulating tu

270 ong entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negat

271 ong entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes.

272 e entire cohort and 7.56% of the subset with metastatic disease to any site.

273 chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination

274 Metastatic disease to the regional LN basin is a strong

275 In patients with metastatic disease, tracer accumulation well above the b

276 o radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic

277 was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarra

278 Uveal melanoma patients with metastatic disease usually die within one year, emphasiz

279 fluoride (NaF PET) for assessment of osseous metastatic disease was associated with substantial chang

280 The likelihood for metastatic disease was scored as low, moderate, or high.

281 f the sentinel-lymph-node-based detection of metastatic disease, was defined as the proportion of pat

282 derstand the nature of candidate targets for metastatic disease, we performed an in silico screen to

283 highlighted when patients with more limited metastatic disease were compared with patients with diss

284 In 28 cases clinical metastatic disease were found.

285 cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or

286 Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and

287 creases overall survival among patients with metastatic disease when it is added to trastuzumab and c

288 static tumor setting, or early vs late stage metastatic disease, when undergoing vector design.

289 dies using models of human or mouse advanced metastatic disease, where the therapeutic advantage of M

290 tary syndrome more frequently presented with metastatic disease, whereas patients with a syndrome wer

291 hment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion

292 rriers to progress is the necessary focus on metastatic disease, which is often challenging, expensiv

293 ave not fully translated to the treatment of metastatic disease, which remains largely incurable.

294 To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and pr

295 Patients with limited metastatic disease who received neoadjuvant chemotherapy

296 ptor 2 (HER2/neu), leading to aggressive and metastatic disease with elevated signaling through PI3K

297 ting chemotherapy demonstrated an absence of metastatic disease with expected avidity in two separate

298 ling relay, may have a therapeutic impact in metastatic disease with lower toxicity than blocking ups

299 uvant trastuzumab or first-line treatment of metastatic disease with trastuzumab.

300 locally advanced disease and all those with metastatic disease) with data collected up to 6 months a